Not available
Quote | Rigel Pharmaceuticals Inc. (NASDAQ:RIGL)
Last: | $1.48 |
---|---|
Change Percent: | -0.67% |
Open: | $1.47 |
Close: | $1.49 |
High: | $1.505 |
Low: | $1.46 |
Volume: | 493,891 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | Rigel Pharmaceuticals Inc. (NASDAQ:RIGL)
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer PR Newswire SOUTH SAN FRANCISCO, Calif. , March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, ...
2024-03-05 22:20:25 ET Rigel Pharmaceuticals, Inc. (RIGL) Q4 2023 Earnings Conference Call March 5, 2024 4:30 AM ET Company Participants Ray Furey - Executive Vice President, General Counsel and Corporate Secretary Raul Rodriguez - President and Chief Executive Offic...
Message Board Posts | Rigel Pharmaceuticals Inc. (NASDAQ:RIGL)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $RIGL 21% v30,2M c1.79 f172,836M H1.83 ML1.43 PMH2.23 S1.56 | znewcar1 | investorshangout | 03/09/2023 3:52:05 AM |
whytestocks: $RIGL News Article - 4 Top Penny Stocks To Watch With Big Biotech News This Quarter | whytestocks | investorshangout | 03/08/2023 3:55:47 PM |
znewcar1: $RIGL thoughts? LL.64 ML1.43 S1.21+1 R1.63+2 + 2.4 | znewcar1 | investorshangout | 03/06/2023 3:16:57 AM |
Expect Q4 filing this week? | bme | investorshub | 02/13/2023 3:37:41 AM |
Be seeing that. Lot of 1.95 transactions so far | bme | investorshub | 01/20/2023 5:55:36 PM |
News, Short Squeeze, Breakout and More Instantly...
Rigel Pharmaceuticals Inc. Company Name:
RIGL Stock Symbol:
NASDAQ Market:
Rigel Pharmaceuticals Inc. Website:
Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer PR Newswire SOUTH SAN FRANCISCO, Calif. , March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, ...
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update PR Newswire Fourth quarter 2023 Total Revenue of $35.8 million which includes TAVALISSE ® net product sales of $25.7 million and REZLIDHIA ® net produ...
Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...